“the AML front-line single-agent study had higher response rates than at the last analysis, which were 42% versus 31.8% for CRs, respectively, and 58% and 41.9% for ORR, respectively. These results compare favorably to the reference data, where CRs are 1-18%. Results for Tibsovo+7+3 were slightly lower than the last analysis with CR+CRi/CRp of 80% versus 90%, respectively, but this analysis included 53% more patients. The results compared favorably to the reference data, where CRs are 70%. The R/R MDS results were very positive, with an ORR of 92%.”
According to TipRanks.com, Cann is a 4-star analyst with an average return of 3.6% and a 42.8% success rate. Cann covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, Miragen Therapeutics Inc, and CytomX Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Agios Pharma with a $83.67 average price target.
The company has a one-year high of $99.82 and a one-year low of $51.62. Currently, Agios Pharma has an average volume of 496.4K.
Based on the recent corporate insider activity of 63 insiders, corporate insider sentiment is neutral on the stock. Most recently, in September 2018, David Schenkein, the CEO of AGIO bought 8,730 shares for a total of $276,217.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.